RecruitingNCT05318196

Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases

Sponsor

University Hospital, Toulouse

Enrollment

5,000 participants

Start Date

Sep 5, 2022

Study Type

OBSERVATIONAL

Conditions

Cancer Metabolic Disease Chronic Kidney Diseases Acute Kidney Injury Solid-organ Transplantation Immune Diseases

Summary

Managing patients with renal failure requires an understanding of the molecular mechanisms that lead to its occurrence (i.e. upstream of the disease), its worsening and its persistence (i.e. downstream), while also specifying the risk of worsening renal failure (risk stratification, intolerance to the treatment or complications (infectious, metabolic, cardiovascular, cancer…). Nephrogene 2.0 aims to study these different components of kidney, immune and solid organ transplantation (SOT)-related diseases.

Eligibility

Min Age: 18 YearsMax Age: 99 Years

Inclusion Criteria2

Patients (\> 18 year of age) with kidney disease or at risk to develop a kidney disease,
Patients followed by a practitioner of the Department of Nephrology and Organ Transplantations of the University Hospital of Toulouse (France)

Exclusion Criteria2

consent deny
inability of the patient or its family to give consent.

Interventions

BIOLOGICALBiological samples collection

SOT patients: samples will be collected at the time of the protocol follow-up visit (registration on the transplant list, on the day of the transplantation, and then at day 15, month 1-3-6-9-12 and then annually, as well as if complications or therapeutic modifications). Dialysis patients: at the start of the dialysis and then at M3, M12, and if complications or modification of the dialysis protocol. Non-dialysis or cancer patients: the sampling frequency will be individualized according to the pathology studied (acute or chronic) and the purpose of the sampling (diagnostic, mechanistic, prediction, evaluation of the therapeutic response). Samples for diagnostic and mechanistic purposes will be taken only once. Samples for prognostic purposes will be taken at regular intervals, adapted to the natural history of the disease while respecting the maximum volume of blood samples defined by the French law. Samples will be collected during a sampling performed as part of routine care.